Bellerophon Therapeutics LLC (Nasdaq: BLPH) presented positive data from a
clinical trial of INOpulse(R) to treat pulmonary arterial hypertension sending the stock price soaring $1.17 to $5.29.
Positive study data for Bellerophon Therapeutics
September 30, 2015 at 14:36 PM EDT